Waypoint Bio – China IIT CAR-T Strategy

Summary Waypoint Bio emerged from stealth with a $20M Series A financing to advance multiple CAR-T investigator-initiated trials in China while developing an AI-enabled spatial pooled screening platform for next-generation target discovery. What Happened Waypoint Bio announced a Series A financing led by Amplify Partners.…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *